Innoviva, Inc. (INVA)

Innoviva's stock price has been influenced by several key events. In July 2025, ZEVTERA was launched in the U.S. In August 2025, Innoviva invested $15.0 million in a term loan to Armata Pharmaceuticals, and a significant portion of the company's 2025 convertible noteholders converted $192.5 million into 11.1 million shares of common stock. In September 2025, Innoviva acquired a proprietary long-acting oral drug delivery platform from Lyndra Therapeutics, Inc. for an upfront payment of $10.2 million, and its portfolio of strategic assets was valued at $483.0 million. In October 2025, Innoviva invested $17.5 million in Beacon Biosignals, Inc., and Innoviva Specialty Therapeutics announced an oral presentation featuring new analyses from the Zoliflodacin pivotal Phase 3 trial at IDWeek 2025. On November 5, 2025, Innoviva reported strong third-quarter 2025 financial results and announced a new $125 million share repurchase program. On November 25, 2025, Innoviva participated in the 37th Annual Piper Sandler Healthcare Conference. On December 11, 2025, Innoviva Specialty Therapeutics announced the publication of positive Zoliflodacin Phase 3 data in The Lancet. On December 12, 2025, the U.S. FDA approved NUZOLVENCE® (zoliflodacin). On December 15, 2025, the PDUFA target action date for zoliflodacin occurred. On January 6, 2026, Innoviva shares closed down 3.59%, and on January 7, 2026, Innoviva shares were trading up 0.56% in pre-market. Recent data indicates that short interest in Innoviva has increased by 10.69%.

Specific detailed information regarding the demand seasonality for Innoviva, Inc.'s products and services is not readily available. While the company's portfolio includes respiratory assets, which might typically experience seasonal demand fluctuations, its focus on critical care and infectious diseases suggests that demand for these treatments may be less subject to seasonal patterns. Seeking Alpha provides a tool to display mean and median monthly returns for INVA to identify seasonal patterns, but the specific data is behind a paywall.

Innoviva, Inc. is a diversified holding company in the Healthcare sector, specifically in Pharmaceuticals and Biotechnology. It operates with a dual-engine business model, generating cash flow from respiratory royalties and driving growth through Innoviva Specialty Therapeutics (IST) and strategic healthcare asset investments. Major products include respiratory assets partnered with Glaxo Group Limited (GSK) such as RELVAR/BREO ELLIPTA and ANORO ELLIPTA. Critical Care and Infectious Disease Therapeutics (Innoviva Specialty Therapeutics - IST) include GIAPREZA, XERAVA, XACDURO, and ZEVTERA. The development pipeline includes Zoliflodacin, an investigational treatment for uncomplicated gonorrhea, which recently received U.S. FDA approval as NUZOLVENCE®.

Innoviva, Inc. is headquartered in Burlingame, California, and its operations are primarily based in the U.S. Its royalty portfolio stems from partnerships with Glaxo Group Limited (GSK), indicating an international reach for its royalty-derived products. Innoviva also has an exclusive distribution and license agreement for ZEVTERA in the U.S.

Innoviva's brand reputation has seen positive developments, including the U.S. FDA approval of NUZOLVENCE® (zoliflodacin) in December 2025. Both ZEVTERA® and XACDURO® were nominated for the 2025 Prix Galien USA Award for Best Pharmaceutical Product. Innoviva also holds a strong market position, scoring higher than 87% of companies evaluated by MarketBeat and ranking 67th out of 914 stocks in the medical sector. Analysts generally view INVA shares optimistically, with a consensus rating of "Moderate Buy."

Innoviva, Inc.'s ownership structure is highly concentrated, with institutional investors and a major corporate partner controlling a significant portion of outstanding shares. Major institutional owners include GlaxoSmithKline PLC, BlackRock, Inc., The Vanguard Group, Inc., Renaissance Technologies LLC, Dimensional Fund Advisors LP, Sarissa Capital Management LP, State Street Corp, and Franklin Resources Inc. Major individual owners (insiders) include Alexander J. Denner and Jeffrey M. Drazan. Institutional ownership is robust, with 581 institutional owners holding a total of 93,515,707 shares.